This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own
View analytic

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Tuesday, March 14



Keynote Franck Petersen - Accessing and leveraging natural products diversity in pharmaceutical research
avatar for Frank Petersen

Frank Petersen

Novartis, Head of Natural Product Group
Frank Petersen heads the natural product group at Novartis and has been involved in the discovery and development of multiple natural product derived clinical candidates, establishing a best in class natural product collection and in the buildup of synthetic biology capabilities at Novartis.

Tuesday March 14, 2017 11:00 - 11:45
Music Hall 2-3-4


Learning from each other - sample logistics in non-small molecule environments Part 1

The challenges of chemical sample management are shared by several neighbouring disciplines in industry and academia. Whilst each discipline has it’s unique problems, the solutions are often founded on common principles that translate across the broader sample management community. In this session, scientists from a diverse array of sample management disciplines will share their distinct experiences, the challenges they’ve overcome in providing a high quality service to support scientific research and development, and highlight the key factors under consideration for future improvements

11.45 Carlo R. Largiadèr
Health-care integrated biobanking, an important resource for precision medicine

Biobanks are essential for biomedical research and, more specifically, for the discovery and development of novel diagnostic biomarkers in the context of personalized medicine. They represent a reservoir for future clinical studies, and thus, accelerate the development and validation of new biomarkers and therapies, while reducing the costs of clinical research. Despite recent methodological advances in “omics-“technologies, the discovery of new biomarkers has been largely prevented by uncontrolled variability in the quality among and within existing biospecimen collections. Therefore, state of the art technological biobank infrastructure that enables researchers to meet the quality requirements of liquid samples is an indispensable precondition for the use of future analytical technologies, such as mass spectrometry. The Inselpital (University Hospital Bern) has implemented for its Liquid Biobank Bern an infrastructure, whose major focus is on sample quality. All pre-analytical processes are fully standardized and  integrated into the clinical routine. Samples are being frozen only one hour after the blood draw with every step in the pre-analytical process being electronically monitored and documented. Such modern health-care integrated and automated biobanks provide an important resource of high quality samples for the application of modern omics-technologies in clinical research. In particular, the ability to document the quality of samples is an important precondition to identify and to account for potential sources of bias that have led to irreproducible published results during the “omics”-hype.

12.10 Alan Brown
Optimising Clinical Laboratory Sample Usage

Every year AstraZeneca clinical studies produce hundreds of thousands of samples. Each and every sample is precious and comes with consent to be used for a specific purpose and has a defined stability. These samples are destined for a huge range of testing from simple safety to complex whole genome sequencing or Bio-banking for future use. Samples are generated and received from investigator sites all over the globe. Once simple, the modern clinical trial is biomarker heavy and often requires complex, multi-step testing using an array of specialist laboratories.

Overseeing the 160 Billion AstraZeneca sample movements each year are the Clinical Sample Scientists. A small operational team working to assist in laboratory selection, operational suitability, clinical trial laboratory set up and conduct.  

In 2016 this team undertook a huge challenge to re-model the way it worked. I will walk you through some of the challenges we faced and how we overcame them. How do we ensure samples from all over the world are fit for purpose? How do we govern the complex vendor landscape? How do we deal with the variable and ever changing regulatory requirements? How did we enable a change that impacted so many important internal and external stakeholders?

12.35 Snapshot Presentation:  

Scott VanderWoude, Wagner Medizin- und Pharmatechnik 

avatar for Clive Green

Clive Green

Director, R&D, Discovery Sciences, AstraZeneca
Clive received undergraduate and postgraduate degrees in Chemistry from the University of Nottingham, UK. He then completed postdoctoral research at the University of Pennsylvania, USA, before returning to the UK in 2001 as a medicinal chemistry Team Leader with AstraZeneca. As a medicinal chemist, Clive delivered projects in the Oncology and Cardiovascular disease areas, spanning all phases of drug discovery research. In 2010, he took up the... Read More →

avatar for Alan Brown

Alan Brown

Associate Director, Clinical Sample Sciences, Astra Zeneca
I graduated with an honours degree in Applied Biology from Brunel University, London. I spent 4 years at Huntingdon Life Sciences working at the bench in an environmental metabolism laboratory using techniques in HPLC and LC-MS to profile the degradation of agricultural and pharmaceutical compound sin simulated environments. I moved to a position of Project Manager for the central laboratory operation of Huntingdon Life Sciences to begin my... Read More →
avatar for Carlo Largiadèr

Carlo Largiadèr

Head of Liquid Biobank Bern, Institute of Clinical Chemistry, Bern University Hospital, University of Bern
Carlo R. Largiadèr (CRL) is a molecular population geneticist. He is currently vice director of the University Institute of Clinical Chemistry (UKC) at the Inselspital and the academic head of the Liquid Biobank Bern (LBB). CRL also heads a research group in pharmacogenomics and drug metabolism at the UKC (http://www.ukc.insel.ch/de/ukc-forschung/pharmacogenomics-and-drug-metabolism/). His current research focuses on genetic and... Read More →

Tuesday March 14, 2017 11:45 - 12:45
Music Hall 1



Learning from each other - sample logistics in non-small molecule environments Part 2

The challenges of chemical sample management are shared by several neighbouring disciplines in industry and academia. Whilst each discipline has it’s unique problems, the solutions are often founded on common principles that translate across the broader sample management community. In this session, scientists from a diverse array of sample management disciplines will share their distinct experiences, the challenges they’ve overcome in providing a high quality service to support scientific research and development, and highlight the key factors under consideration for future improvements

14.00 Ida Isaksson
New modalities, new processes: addressing sample management challenges with biologicals in early research

Biologicals (linear peptides, macrocycles, nucleosides, protein, sugars and more) are rapidly becoming ligand options for targets of interest in big pharma drug discovery portfolios, alongside small molecules. How does compound management adapt to the needs of these "new modalities"? Work is in progress in AstraZeneca to answer this question, to implement sustainable processes while ensuring sample quality and data integrity. While some existing processes and IT tools established over the years can be adjusted to fit the new requirements, biologicals pose different challenges compared to small molecules when it comes to storage conditions, solvents and metadata which requires the introduction of new technological capabilities. 

Our current focus is on peptides, proteins and genome editing libraries. Examples of work being undertaken includes sample-specific storage conditions to ensure quality, workflow enhancements in sample management system and introduction of liquid handling systems with multiple fluid capability. Current sample registration system is also developed to cater for different sample properties which enables comparison of screening data from different modalities easily. Together these changes maximize the utilisation of new modalities to support our drug discovery research.

14.30 James Johnson, Manager of the GeneMill facility
Challenges for management and tracking in SynBio

avatar for Clive Green

Clive Green

Director, R&D, Discovery Sciences, AstraZeneca
Clive received undergraduate and postgraduate degrees in Chemistry from the University of Nottingham, UK. He then completed postdoctoral research at the University of Pennsylvania, USA, before returning to the UK in 2001 as a medicinal chemistry Team Leader with AstraZeneca. As a medicinal chemist, Clive delivered projects in the Oncology and Cardiovascular disease areas, spanning all phases of drug discovery research. In 2010, he took up the... Read More →


James Johnson

James is currently the Manager of the GeneMill facility, an open-access Synthetic Biology “Foundry”. He read Applied Biochemistry at the University of Liverpool, during which time he worked for F. Hoffmann-La Roche Ltd in Basel, Switzerland. After completing his PhD in Molecular Cell Biology in Mike White’s lab, he went on to work with Bob Burgoyne, Alan Morgan and Jeff Barclay in Liverpool, where he introduced and developed new processes... Read More →

avatar for Brooks


Brooks is a leading worldwide provider of automation and cryogenic solutions for multiple markets including semiconductor manufacturing and life sciences. Brooks Life Science Systems is the global leader in automated sample management solutions that ensure cold-chain integrity from room temperature to -190° C. The company provides unparalleled experience in cold chain management that removes risk and uncertainty from your process... Read More →

Tuesday March 14, 2017 14:00 - 14:50
Music Hall 1


Challenges of outsourcing

The general trend of outsourcing in the pharmaceutical industry did not stop at sample and compound management area. While that key component of early drug discovery was formerly kept within the pharma companies the more recent developments indicate changes in strategy.

Aspects driving decisions to externalize compound management efforts and challenges connected to that will be discussed. Topics highlighted cover strategic considerations, investments and expertise but also the question whether outsourced compound management can provide services of highest quality within turnaround times as internal facilities can do. We will get insight from various angles with the experience of outsourcing pharma companies and the perspective of research organizations providing such services.

14.50 Olivier Casamitjana 
Challenges of outsourcing

The general trend of outsourcing in the pharmaceutical industry did also expanded to sample and compound management area. While that key component of early drug discovery was formerly kept within the pharma companies, because it was considered as an internal asset, a family jewel. The more recent developments indicate changes in strategy, affecting all companies’ types (big pharma, mid-size pharma, virtual biotech).Multiple aspects discussed in the session suggest considering such externalization efforts but also challenges connected to outsourcing will be highlighted. Those refer always to investments and expertise but also the question whether outsourced compound management can provide services of same quality within turnaround times as internal facilities can do. In the same time, building an internal Compound management costs a lot and does not allow an easy return of investment, rather than outsourcing gives this advantage. In the end, the key questions become again how to build the trust? How to build the transition phase to become partners? Moreover, to do a Pros/cons analysis to convince the management…I will get insight from various angles including the experience of outsourcing pharma companies but also the perspective of research organizations providing such services.

15.20 Rose Gonzales
Evaluation of Resourcing Options for Compound Management Workflows

An extensive evaluation of resourcing options was conducted for a discrete set of compound management workflows focused on the stewardship of Pfizer's compound collection.  The resourcing options considered were: (1) Transfer to a third party, (2) In house management through contingent workers, (3) Insourcing through a dedicated third  party on site in Groton.  This presentation will go through the information gathering, analysis, recommendations, and decisions taken.  Finally, a review of current state of implementation 12 months post decision will also be presented.

15.50 Elizabeth Admirand
Ensuring Data Quality in an Outsourcing Environment:How Epizyme Conducted Detailed CRO Site Checks ona Global Scale

In an effort to reduce costs, the outsourcing community is seeing an increase in business. For Epizyme, nearly 70% ofresearch is being conducted at Contract Research Organizations. In this talk, we discuss how fine tuning outsourcedsite processes has ensured data integrity during tech-transfers. Conducting site checks around the world has aided inthe understanding of varied capabilities of different contract partners, allowing us to manage internal and externalexpectations accordingly. By establishing sample handling guidelines through written and in-person communication,Epizyme has unearthed key red flags to look for in order to maintain a high level of quality.

16.20 Ludovic Otterbein
Outsourcing of Early Discovery Processes

A large proportion of Lundbeck’s Research budget is allocated to external collaborations around the world. These sets of strategic initiatives have an impact on the internal operating models for early and late discovery. From chemistry to compound management and screening, we have defined outsourcing models based on different drivers: capacity, capability, flexibility & cost in order to support our research ambitions. This presentation will highlight our current operating models for early discovery, the rationale and also the complexity &challenges associated.

avatar for Dirk Winkler

Dirk Winkler

VP Biophysics and Compound Management, EVOTEG AG
Dirk Winkler is in charge of Biophysics and Compound Management at Evotec AG, Hamburg, Germany. After receiving his Ph.D. from the University of Leipzig, Germany he started his industrial career in 1998 at Evotec. In his current role Dirk is also responsible for Evotec’s screening library, including various aspects of compound handling as well as library maintenance and improvement. Based on his background as an organic chemist he is... Read More →


Elizabeth Admirand

?, Epizyme
Elizabeth has been working in the Lead Discovery group at Epizyme for the past 4.5 years with a primary focus inCompound Management and Biochemistry. Applying her knowledge of compound management, biochemistry, andinformatics, Elizabeth has been able to successfully conduct diligence checks at multiple CROs and aid in the decisionto initiate work with new partners. Elizabeth was previously employed at Proteostasis Therapeutics in Cambridge... Read More →
avatar for Olivier Casamitjana

Olivier Casamitjana

Senior VP, Global Compound Management Head, EVOTEC France
Engineer by training in biological sciences, Olivier Casamitjana acquired more than 18 years of experience in the pharmaceutical industry. Successively at Pfizer and then Solvay-Fournier, Olivier worked in the domains of assay development, high throughput screening and management of sample patrimony. Then Olivier worked within Sanofi during 10 years. He was successively project leader of large automated stores for compound management and of a... Read More →
avatar for Rosalia Gonzales

Rosalia Gonzales

Director, Pfizer, Inc.
Rose Gonzales is Director of Compound Management & Distribution (CMD) at Pfizer Worldwide Research & Development, based in Groton, CT.   She has been at Pfizer for 17 years, the last 7 in her current role overseeing the compound collection of Pfizer.  Rose has undergraduate and graduate degrees in Chemicial Engineering; her PhD thesis was in the area of cell adhesion under low shear stress conditions.  Previous to... Read More →
avatar for Ludovic Otterbein

Ludovic Otterbein

Director Research Informatics, Lundbeck
In charge of Research Informatics, Compound Management and Analytical Chemistry within Lundbeck, I focus on setting the strategic direction of the group and its implementation. | Our compound management area receives, manages and delivers compounds to the entire research organisation using optimized processes and state of the art automation. We have in the last few years internalize the management of our liquid collection after few years of... Read More →

Tuesday March 14, 2017 14:50 - 16:50
Music Hall 1


Coffee Break
Tuesday March 14, 2017 16:50 - 17:20
Music Hall 2-3-4


Interactive Session: What’s Hot in Commercial Technology and Services?

In this session services and technology providers will share a brief background to their company before focussing on their latest product/service developments. The presentations will include the business problem the product/service is designed to solve and the alignment with their broader product/service offerings.

Paul LomaxProduct Manager at TTP Labtech

Ariane Jonetz-Mentzel, Product Manager Liquid Handling, Analytik Jena AG
Overcome bottlenecks in MALDI sample plate preparation 1536 parallel pipetting – beyond just spotting

Brad Nelson, Sr. Director, Corporate Development/Strategy Labcyte

Dr. Jan Breitenfeld, Chemspeed
Revolution of Reformatting in Compound Management: High-Throughput Product Development in Life Science

David Booth, Titian 

Tobias Haessner,
LVL Technologies 

Tuesday March 14, 2017 17:20 - 18:45
Music Hall 1


Networking Drink
Enjoy a drink in the exhibition area with friends and colleagues!

Tuesday March 14, 2017 18:45 - 19:45
Music Hall 2-3-4


A sit-down dinner will be served at the NHOW restaurant. Join us for an evening of good food and networking!

Tuesday March 14, 2017 19:45 - 22:15
NHOW Restaurant
Wednesday, March 15


Interactive Session: How to Get Funding Internally?
This session will engage attendees to share experiences and informally debate critical success factors to increase your likelihood of success in securing support for new technology ideas. 

Come and contribute with your views and questions! 


Marybeth Burton

Director, Merck Research Laboratories

Wednesday March 15, 2017 08:30 - 09:45
Music Hall 1


Coffee Break
Wednesday March 15, 2017 09:45 - 10:30
Music Hall 2-3-4


Innovation in Compound Management
Driven by increasing customer demands in the face of limited resources, compound managers need to continually improve equipment, internal processes as well as external interfaces to remain viable in the time-restricted, labor-intensive, highly competitive field of early drug discovery. The same time, technological advances and breakthroughs in compound storage, handling, and quality control don not only offers the solution for existing problems but even provoke the rethinking of existing processes. This session will present case studies from industry sharing firsthand experience with cutting-edge innovation in sample management, as well as perspectives from academic labs on how groundbreaking technologies may shape the future of compound logistics.

10.30 Inge Moelans
Janssen’s Compound Logistics 2016+ Upgrade Project: From Starfish to Octopus

In 2016 Janssen decided to upgrade their Compound Logistics facilities globally.
To  ensure that we deliver the promise and vision that “Compound Logistics is a state of the art global organization  that cares for the Janssen Compound Library and flawlessly feeds all Janssen compound related (early) research activities (internally as well as externally) with high quality compound samples in a standardized manner” a global project has been initiated to enable the implementation of Efficient and State-Off-The-Art Compound Management Infrastructures and Processes to support Drug Discovery Goals. As a result several new hardware and software systems will become available across three Compound Management sites in 2017-2018. The integrated combination of optimized hardware and software systems will lead to reduced cycle times, efficient, standardized & flexible compound processing and high quality samples. 

10.55 Mark Gulbronson
Metrics, Process Efficiency, and Flexibility

Amgen’s Research Materials Management group was originally built to manage the research small molecule collection. The software, automation, and processes put in place allowed us to grow the collection 10-fold while simultaneously reducing staffing requirements. This presentation explores lessons learned in two areas: Are we efficient? Are we flexible?

Are we efficient? Research Materials Management, as part of a collaborative team, examined the processing and movement of molecules from submission through assay results generation. The analysis identified the impact of distributed Amgen sites and outsourcing partners, internal scheduling, and queue wait times for constrained and unconstrained resources.

Are we flexible? When we looked to apply our proven strategies to biologics inventory management and processes in the biology labs, we were faced with significant challenges. In addition to the new lower temperature storage requirements, the biology labs typically did not use automation, barcodes, standard consumables, or proper inventory systems. In addition, tubes representing years of research were distributed around the world in hundreds of freezers and LN2 tanks. 

11.20 Phil Spencer
Introducing AstraZeneca’s Global Capability for Acoustic Tubes

AstraZeneca is collaborating with Labcyte and others to transform the use and benefit of its automated compound plate production systems in the new UK Centre for Lead Discovery at Cambridge and at its sites in Gothenburg and Boston. Through the development of novel miniaturised liquid storage vessels, dispensing devices and automated workcells, the collaborations will deliver a new global capability for acoustic dispensing direct from sample storage tubes. For the first time, compound screening plates will be produced entirely by acoustic dispensing, completely eliminating pipette-based liquid transfer methods and providing an unparalleled level of quality in the screening data delivered to drug discovery projects.This presentation will cover the drivers for AstraZeneca pursuing this innovative approach and the benefits and impacts for Compound Management and its customers. Details of AstraZeneca’s new global business processes and progress on development of novel technologies with its collaborators will also be included.

11.45 Susan Crimmin

A Sample Management Strategy for the Modern Drug Discovery

Sample management has traditionally been based around small molecule collections and processes.
In the last few years we have come to realize that the Pharma landscape is changing. With that comes increasing challenges but also significant opportunities for sample management organizations to help support that changing landscape.  This talk will focus on the transitions made within GSK to meet the changing face of drug discovery. 


Donat Elsener, 
Director of Sales and Marketing, Hamilton Storage

Not Only ‘Think Big’

Dr. Martin Brunner, Principal Scientist Compound Logistics, from Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Ltd Specs

avatar for Jan Eickhoff

Jan Eickhoff

Head of Assay Development / Screening, Lead Discovery Center GmbH
Jan Eickhoff studied biochemistry at the University Bayreuth and Imperial College in London, followed by PhD studies at the Max-Planck-Institute of Biochemistry in Martinsried. He started his industrial career in 2001 at Axxima Pharmaceuticals, and GPC Biotech, before he moved to Dortmund in 2008 to build up the screening and sample management department of the Lead Discovery Center GmbH (LDC). Furthermore, he was involved in conceptual... Read More →

avatar for Susan Crimmin

Susan Crimmin

Vice president of Discovery Supply, GSK
Dr Sue Crimmin is VP and global head of Discovery Supply at GSK.  This worldwide organization is accountable for the acquisition, development and management of GSK biological (including Human Biological Samples) & small molecule collections and the maintenance & distribution of preclinical, clinical and post clinical trial samples and collections including compliance and QA.  She is a recognized industry expert in sample... Read More →
avatar for Mark Gulbronson

Mark Gulbronson

Director Research Operations, Amgen
Mark Gulbronson, Director Research Operations, is head of Amgen’s Research Materials Management organization. With operations in California and Massachusetts, his team is responsible for the curation and worldwide distribution of Amgen’s small molecule and biologics collections. Mark has contributed to pharmaceutical research for 30 years as a cardiovascular biologist, software developer, and operations manager at Bristol-Myers... Read More →
avatar for Inge Moelans

Inge Moelans

Global Head Compound Logistics, Janssen Research and Development
Inge Moelans is head of the Compound Logistics group within the Discovery Sciences organization at Janssen Research and Development. After completion of her masters in Biology and Chemistry, with specializations in Molecular Biology and Pharmacology, she received a Ph.D. in Sciences at the University of Nijmegen, The Netherlands. In addition, she worked as a post-doc in the Eijkman-Winkler Institute of Medical Microbiology in Utrecht, The... Read More →
avatar for Philip Spencer

Philip Spencer

Team Leader Compound Management, AstraZeneca
Phil Spencer has more than fifteen years experience working in Compound Management. From 2000 he was Head of Compound Management at AstraZeneca’s Charnwood site, where he established an Automated Compound Management Facility to support High Throughput Screening. | | In 2011, Phil moved to the Compound Management group at Alderley Park, where he launched New Molecule Profiling within AstraZeneca’s Open Innovation program, offering... Read More →

Wednesday March 15, 2017 10:30 - 12:30
Music Hall 1


Networking Lunch
Wednesday March 15, 2017 12:30 - 14:00
Music Hall 2-3-4


Industry-academia research collaborations
It is well recognised that pharma industry is changing, especially in the field of early drug discovery. The concept of open innovation is embraced and collaborations between academia and industry are setup to fill the emerging gap in drug discovery. On the one hand, academia is moving into the field of screening and compound management, on the other hand, industry is making their compound collections available to a wider scientific community. This session will show how these developments impact compound management and how industry and academia are making progress in combining the best of both worlds.

14.00 Yoichi Kurebayashi
Mission and Strategy of Japan Agency for Medical Research and Development for Boosting Drug Discovery in Japan

Slow development in clinical application and commercialization of outcomes from basic researches has been a long standing issue in Japan. In this context, a new funding agency, Japan Agency for Medical Research and Development (AMED), was established in 2015 to accelerate and innovate the medical research and development in Japan. In AMED, the department of innovative Drug Discovery and Development (iD3) is taking the initiative in drug discovery and development domain. The missions of iD3 include 1) accelerating translation of promising basic researches into innovative medicines, 2) promoting development of innovative translational sciences enabling more efficient drug discovery and development, and 3) creating and expanding precompetitive collaboration space in Japan. In this session, iD3’s new national projects for boosting collaborative drug discovery, i.e., iD3 Booster, Drug Discovery Support Network and Joint Pharma-compound Library initiative, will be presented.

14.30 Constantin Radu
The NTD Drug Discovery Booster: A Disruptive Approach to Chemical Screening

Small molecule screening has developed over the years from the early 1940’s, testing small molecules in test tubes, to technological breakthroughs leading to high throughput screening (HTS) in the 1990’s, in the efforts to discover pharmacological active molecules and subsequently leading to a lead molecule. The Drugs for Neglected Diseases initiative (DNDi), in conjunction with several consortium partners, have developed a disruptive approach to drug discovery, the NTD Drug Discovery Booster, to effectively maximise the Structure-Activity Relationship (SAR) space around new chemical hits and leads targeting Leishmania donovani and Trypanosoma cruzi, the kinetoplastid parasites responsible for visceral leishmaniasis and Chagas disease respectively. Institut Pasteur Korea (IPK) was selected as the screening hub for sample preparation and screening of small molecules distributed by the NTD Booster consortium members, where each member mines their own chemical library based on lead chemical series and ships it to IPK for process. The IPK Automation & Logistics Management (ALM) group is accountable for the logistical framework of importing the small molecules from various global locations and implementing good sample management practices with a strategic approach, taking into consideration compound stability and integrity. The objective of this presentation will be to show the logistical effort that is needed to import and manage small molecules as part of a multi-nations consortium and identifying a lead candidate.The NTD Drug Discovery Booster consortium currently consists of AstraZeneca plc., Celgene Corporation, Eisai Co, Ltd., Shionogi & Co, Ltd., Takeda Pharmaceutical Ltd., the Drugs for Neglected Diseases initiative and Institut Pasteur Korea.

15.00 Dr Kristian Birchall

Key Considerations in Compound Collection Composition and Quality – Seeding Success in Hit Follow Up

The adage “garbage in, garbage out” is painfully true in HTS. Attrition at the stage of hit triage is a frustrating waste of resource, especially given the repeated deployment of a screening collection, the difficulty of removing troublesome compounds and the consequences of following up poor quality hits. Thankfully there is an increasing awareness of the factors associated with poor prognosis, including physicochemical property profiles (e.g. QED score) and sub-structural flags (e.g. PAINS). However, many more subtle combinations of factors such as the location and frequency of undesirable groups alongside synthetic tractability can also diminish the prospects of a compound in hit follow up. Whilst it can be difficult to develop a set of rules that cover all possible scenarios, undesirable compounds can easily be spotted by experienced medicinal chemists. We describe a “wisdom of crowds” approach used as the final step when building our compound collection.

Other examples of strategies employed to improve the chance of success will be described including; the use of upfront experimental data to steer compound selection away from off-target liabilities, the use of target-focussed sets to improve hit rates and the use of knowledge-annotated and index sets to expedite hit follow up.

15.45: Closing remarks 

avatar for Steven Van Helden

Steven Van Helden

Business Development & Account Management, Pivot Park Screening Centre
Steven van Helden studied chemistry at Utrecht University and, after obtaining his Ph.D. , worked for 20 years in various roles in pharmaceutical industry. Since 2003 he has been responsible for High Throughput Screening (HTS) operations and strategy at Organon/MSD. After the  closure of  those research facilities he developed a business plan for continuation of the screening activities in Oss, The Netherlands. This led to the formation... Read More →

avatar for Kristian Birchall

Kristian Birchall

Senior Scientist (Modelling and Informatics), MRC Technology
Kristian gained his first taste of the challenges encountered in drug discovery doing QSAR and microarray data analysis during industrial placements whilst studying for a masters in biochemistry at the University of Bath. He undertook a CASE studentship between the University of Sheffield and GSK Stevenage, working on molecular similarity multi-objective optimisation algorithms. Enjoying pharmaceutical research at the interface between industry... Read More →
avatar for Yoichi Kurebyashi

Yoichi Kurebyashi

Senior Director, Japan Agency for Medical Research and Development (AMED)
In 1979, Yoichi Kurebayashi started his industry career at Daiichi Pharmaceutical Co. Ltd as a medicinal biologist. Later he served as Head of the Institute of Allergy at Bayer’s Research Center Kyoto and Vice President of Discovery Research Japan at Pfizer Global Research and Development, during which time he led multiple global project teams for drug discovery and development. In 2007, taking advantage of the long industry experience, he... Read More →
avatar for Constantin Radu

Constantin Radu

Group Head, Institut Pasteur Korea
Constantin Radu is the Head of the Automation and Logistics Management group at the Institut Pasteur Korea (IPK), in Seoul, South Korea, since January 2015. His group is responsible for supporting screening campaigns for infectious and neglected diseases, using dynamic robotic platforms and high content microscopy, as well as the management of the chemical and RNAi libraries and logistics management for the institute. Prior to joining IPK, he has... Read More →

Wednesday March 15, 2017 14:00 - 16:00
Music Hall 1


Closing Coffee
Wednesday March 15, 2017 16:00 - 16:30
Music Hall 2-3-4